Research ExplorerPublicationsBiochemical Recurrence in Prostate Cancer: The European Asso...

Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations

Standard

Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. / Van den Broeck, Thomas; van den Bergh, Roderick C N; Briers, Erik; Cornford, Philip; Cumberbatch, Marcus; Tilki, Derya; De Santis, Maria; Fanti, Stefano; Fossati, Nicola; Gillessen, Silke; Grummet, Jeremy P; Henry, Ann M; Lardas, Michael; Liew, Matthew; Mason, Malcolm; Moris, Lisa; Schoots, Ivo G; van der Kwast, Theodorus; van der Poel, Henk; Wiegel, Thomas; Willemse, Peter-Paul M; Rouvière, Olivier; Lam, Thomas B; Mottet, Nicolas.

In: EUR UROL FOCUS, Vol. 6, No. 2, 15.03.2020, p. 231-234.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Van den Broeck, T, van den Bergh, RCN, Briers, E, Cornford, P, Cumberbatch, M, Tilki, D, De Santis, M, Fanti, S, Fossati, N, Gillessen, S, Grummet, JP, Henry, AM, Lardas, M, Liew, M, Mason, M, Moris, L, Schoots, IG, van der Kwast, T, van der Poel, H, Wiegel, T, Willemse, P-PM, Rouvière, O, Lam, TB & Mottet, N 2020, 'Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations', EUR UROL FOCUS, vol. 6, no. 2, pp. 231-234. https://doi.org/10.1016/j.euf.2019.06.004

APA

Van den Broeck, T., van den Bergh, R. C. N., Briers, E., Cornford, P., Cumberbatch, M., Tilki, D., De Santis, M., Fanti, S., Fossati, N., Gillessen, S., Grummet, J. P., Henry, A. M., Lardas, M., Liew, M., Mason, M., Moris, L., Schoots, I. G., van der Kwast, T., van der Poel, H., ... Mottet, N. (2020). Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. EUR UROL FOCUS, 6(2), 231-234. https://doi.org/10.1016/j.euf.2019.06.004

Vancouver

Van den Broeck T, van den Bergh RCN, Briers E, Cornford P, Cumberbatch M, Tilki D et al. Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. EUR UROL FOCUS. 2020 Mar 15;6(2):231-234. https://doi.org/10.1016/j.euf.2019.06.004

Bibtex

@article{303029f5823344b5b176823f4aaa6a8d,
title = "Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations",
abstract = "Biochemical recurrence (BCR) after primary treatment of localized prostate cancer does not necessarily lead to clinically apparent progressive disease. To aid in prognostication, the European Association of Urology prostate cancer guidelines panel undertook a systematic review and successfully developed a novel BCR risk stratification system (groups with a low risk or high risk of BCR) based on disease and prostate-specific antigen characteristics. PATIENT SUMMARY: Following treatment to cure prostate cancer, some patients can develop recurrence of disease identified via a prostate-specific antigen blood test (ie, biochemical recurrence, or BCR). However, not every man who experiences BCR develops progressive disease (symptoms or evidence of disease progression on imaging). We conducted a review of the literature and developed a classification system for predicting which patients might progress to optimize treatment decisions.",
author = "{Van den Broeck}, Thomas and {van den Bergh}, {Roderick C N} and Erik Briers and Philip Cornford and Marcus Cumberbatch and Derya Tilki and {De Santis}, Maria and Stefano Fanti and Nicola Fossati and Silke Gillessen and Grummet, {Jeremy P} and Henry, {Ann M} and Michael Lardas and Matthew Liew and Malcolm Mason and Lisa Moris and Schoots, {Ivo G} and {van der Kwast}, Theodorus and {van der Poel}, Henk and Thomas Wiegel and Willemse, {Peter-Paul M} and Olivier Rouvi{\`e}re and Lam, {Thomas B} and Nicolas Mottet",
note = "Copyright {\textcopyright} 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.",
year = "2020",
month = mar,
day = "15",
doi = "10.1016/j.euf.2019.06.004",
language = "English",
volume = "6",
pages = "231--234",
journal = "EUR UROL FOCUS",
issn = "2405-4569",
publisher = "Elsevier BV",
number = "2",

}

RIS

TY - JOUR

T1 - Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations

AU - Van den Broeck, Thomas

AU - van den Bergh, Roderick C N

AU - Briers, Erik

AU - Cornford, Philip

AU - Cumberbatch, Marcus

AU - Tilki, Derya

AU - De Santis, Maria

AU - Fanti, Stefano

AU - Fossati, Nicola

AU - Gillessen, Silke

AU - Grummet, Jeremy P

AU - Henry, Ann M

AU - Lardas, Michael

AU - Liew, Matthew

AU - Mason, Malcolm

AU - Moris, Lisa

AU - Schoots, Ivo G

AU - van der Kwast, Theodorus

AU - van der Poel, Henk

AU - Wiegel, Thomas

AU - Willemse, Peter-Paul M

AU - Rouvière, Olivier

AU - Lam, Thomas B

AU - Mottet, Nicolas

N1 - Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.

PY - 2020/3/15

Y1 - 2020/3/15

N2 - Biochemical recurrence (BCR) after primary treatment of localized prostate cancer does not necessarily lead to clinically apparent progressive disease. To aid in prognostication, the European Association of Urology prostate cancer guidelines panel undertook a systematic review and successfully developed a novel BCR risk stratification system (groups with a low risk or high risk of BCR) based on disease and prostate-specific antigen characteristics. PATIENT SUMMARY: Following treatment to cure prostate cancer, some patients can develop recurrence of disease identified via a prostate-specific antigen blood test (ie, biochemical recurrence, or BCR). However, not every man who experiences BCR develops progressive disease (symptoms or evidence of disease progression on imaging). We conducted a review of the literature and developed a classification system for predicting which patients might progress to optimize treatment decisions.

AB - Biochemical recurrence (BCR) after primary treatment of localized prostate cancer does not necessarily lead to clinically apparent progressive disease. To aid in prognostication, the European Association of Urology prostate cancer guidelines panel undertook a systematic review and successfully developed a novel BCR risk stratification system (groups with a low risk or high risk of BCR) based on disease and prostate-specific antigen characteristics. PATIENT SUMMARY: Following treatment to cure prostate cancer, some patients can develop recurrence of disease identified via a prostate-specific antigen blood test (ie, biochemical recurrence, or BCR). However, not every man who experiences BCR develops progressive disease (symptoms or evidence of disease progression on imaging). We conducted a review of the literature and developed a classification system for predicting which patients might progress to optimize treatment decisions.

U2 - 10.1016/j.euf.2019.06.004

DO - 10.1016/j.euf.2019.06.004

M3 - SCORING: Journal article

C2 - 31248850

VL - 6

SP - 231

EP - 234

JO - EUR UROL FOCUS

JF - EUR UROL FOCUS

SN - 2405-4569

IS - 2

ER -